Navigation Links
New Blood Thinner May Help Prevent Leg Clots, Study Finds

By Steven Reinberg
HealthDay Reporter

SATURDAY, Dec. 8 (HealthDay News) -- The new anti-clotting drug apixaban (Eliquis) appears to help prevent potentially fatal blood clots in patients with deep vein thrombosis (DVT), a new Italian study finds.

People who suffer from venous thromboembolism are prone to develop blood clots in the veins in their legs (DVT). If a clot breaks loose, it can travel to the heart and cause a heart attack, or the brain and cause a stroke, or to the lungs and cause severe breathing difficulties, and even death.

"This finding is great," said Dr. Maja Zaric, an interventional cardiologist at Lenox Hill Hospital in New York City.

Currently, patients with recurrent venous thromboembolism take a drug called warfarin, which is effective but needs careful monitoring and is associated with a risk of major, and sometimes fatal, bleeding.

This drug and others will likely replace warfarin over the next few years, Zaric said. These drugs do not require weekly or monthly blood tests, which is a major problem for many patients, she explained.

"One drawback of apixaban is having to take two doses a day," Zaric said. "This can make patient compliance less effective. The drug that will be the one most used is the cheapest one that only has to be taken once a day."

Although apixaban and other drugs in its class cost more initially, not having to make frequent doctor visits to check medication levels along with not having as many severe bleeding episodes as with warfarin will save more in the long run, Zaric pointed out.

"It's cheaper to spend a little more on a drug than a lot on doctor's visits and hospitalizations," Zaric said.

A month's treatment with warfarin costs about $35 in Canada, where apixaban is available with a monthly price tag of $290, according to the Canadian drug index of Rx List.

The findings were published online Dec. 8 in the New England Journal of Medicine, to coincide with a planned presentation at the American Society of Hematology annual meeting in Atlanta.

Dr. Giancarlo Agnelli, director of the department of internal and cardiovascular medicine and stroke unit at Perugia University Hospital in Italy, and his colleagues randomly assigned almost 2,500 patients to one of three regimens for a year.

Patients were either given 2.5 milligrams (mg) of apixaban twice daily, 5 mg of apixaban twice daily or an inactive placebo. Over the course of the trial, the researchers looked for recurrent venous thromboembolism, deaths from venous thromboembolism or cardiovascular problems and major bleeding.

The investigators found that either dose of apixaban reduced the risk of recurrent venous thromboembolism and venous thromboembolism-related death by about 80 percent, compared with placebo.

While almost 9 percent of those receiving placebo had one of these events, only 1.7 percent of those taking apixaban did, the researchers reported.

In addition, either dose of apixaban reduced the risk of stroke, heart attack and cardiovascular-related death. Major bleeding was similar for those taking apixaban and those receiving placebo, the researchers noted.

"These results indicate that apixaban -- at both low and high doses -- provides an attractive risk-benefit profile for use as an ongoing treatment option in patients at risk of recurrent [venous thromboembolism]," Agnelli said in a statement.

"This regimen has the potential to eliminate many of the challenges we face when we treat patients with warfarin -- including drug and food interactions and the need for ongoing monitoring -- which can greatly simplify ongoing management of this condition," he added.

The trial was funded by the developers of apixaban, Bristol-Myers Squibb and Pfizer. Although the drug has not yet been approved by the U.S. Food and Drug Administration, a decision is expected in March, according to the agency. Approval was delayed because the FDA asked for more data.

Drugs similar to apixaban include Xarelto (rivaroxaban) and Pradaxa (dabigatran etexilate), both of which have been approved by the FDA.

According to the U.S. Centers for Disease Control and Prevention, about one-third of patients who have suffered venous thromboembolism have a recurrence within 10 years.

Another expert, Dr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, said that "after venous thromboembolism, it is recommended that patients be treated with anticoagulation therapy for six to 12 months. However, the benefits and risks of extended treatment with new oral anticoagulant agents are unclear. Given the highly favorable benefit/risk ratio, the extended treatment approach may represent an important therapeutic advance."

More information

For more information on venous thromboembolism , visit the U.S. National Library of Medicine.

SOURCES: Maja Zaric, M.D., interventional cardiologist, Lenox Hill Hospital, New York City; Gregg Fonarow, M.D., spokesman, American Heart Association, and professor, cardiology, University of California, Los Angeles; Dec. 8, 2012, New England Journal of Medicine, online; Dec. 8, 2012, presentation, American Society of Hematology annual meeting, Atlanta

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. US Drug Watchdog Now Urges All DePuy ASR And DePuy Pinnacle Hip Implant Recipients To Get Blood Tests And To Call Them For The Names Of The Best Law Firms-Get Compensated
2. Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
3. Consider Weight When Choosing Blood Pressure Meds: Study
4. Honey Hollow Wagyu Announces New eCommerce Website to Bring Simplicity to Ordering 100% FullBlood Wagyu Beef Online
5. Studying marrow, URMC researchers accelerate blood stem cells
6. Unexpected toughness may mark out cancer cells in the blood
7. US Drug Watchdog Now Urges All DePuy Pinnacle Hip Implant Recipients To Get A Blood Test For Elevated Levels Of Cobalt Or Chromium and to Call Them If The Levels Are high
8. New DNA-Based Blood Test May Spot Signs of Cancer
9. Johns Hopkins scientists pair blood test and gene sequencing to detect cancer
10. High Blood Pressure During Pregnancy Tied to Later Heart Trouble
11. Impaired blood vessel function found in cystic fibrosis patients
Post Your Comments:
Related Image:
New Blood Thinner May Help Prevent Leg Clots, Study Finds
(Date:11/27/2015)... ... November 27, 2015 , ... ... through sharing, the 2016 Building Better Radiology Marketing Programs meeting will ... on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a ...
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, ... posters. This is one of Joplin's most famous and beautiful concert posters. The concert ... Michigan in Ann Arbor. The According to Hawley, "It is hard to believe that ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... real-time eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean ... Nuclear Medicine tests directly from their electronic medical record (EMR) without the need ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating ... our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment ... day excited to rebuild lives and it’s an honor to have served all of ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Therapeutic Drug Monitoring ... Forecasts, Competitive Intelligence, Emerging Opportunities"  report ... ) has announced the addition ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
Breaking Medicine Technology: